New combo shows promise for rare adrenal cancer
NCT ID NCT05036434
First seen Jan 31, 2026 · Last updated May 19, 2026 · Updated 16 times
Summary
This study tests a combination of two drugs, pembrolizumab and lenvatinib, in people with advanced adrenal cortical carcinoma that has not responded to standard chemotherapy. The goal is to see if this treatment can shrink or control the cancer. About 30 adults will take part, receiving the drugs through an IV and by mouth.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADRENOCORTICAL CARCINOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Cancer Center
Goyang-si, Gyeonggi-do, 10408, South Korea
Conditions
Explore the condition pages connected to this study.